Goldman Sachs Reiterates Buy Rating on Stoke Therapeutics (STOK) Post Investor Meeting
Tweet Send to a Friend
Goldman Sachs analyst Kevin Strang reiterated a Buy rating and $44.00 price target on Stoke Therapeutics (NASDAQ: STOK).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
